文献速递妇科肿瘤

卵巢癌应用ESTRO-EORTC寡转移分类系统的挑战

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.
PubMed 文献 · Lancet Oncol · 2026-01-01

该文讨论ESTRO-EORTC寡转移疾病分类系统在卵巢癌中的应用挑战,指出卵巢癌早期弥漫性腹膜播散和腹膜病灶难以 discrete 计数两大疾病特征限制该分类系统的适用性。作者主张由ESTRO-EORTC与欧洲妇科肿瘤学会联合制定卵巢癌特异性腹膜病变规则,以改善患者分层和临床试验入组。

要点

  • 卵巢癌弥漫性腹膜播散和病灶难以计数限制ESTRO-EORTC寡转移分类系统的应用。
  • 立体定向放疗可在全身治疗基础上为精选低转移负荷患者实现持久局部控制。
  • 建议联合制定卵巢癌特异性腹膜病变分类规则以统一临床实践和试验入组。

核心结论

  • ESTRO-EORTC寡转移分类系统直接用于卵巢癌存在困难,需制定卵巢癌特异性规则以改善分层和治疗规划。

研究设计与样本

  • 本文为来自Lancet Oncology的评论/观点文章,讨论ESTRO-EORTC寡转移分类系统在卵巢癌中的应用挑战,未报告原始研究样本。

主要发现

  • 卵巢癌早期且常为弥漫性腹膜播散以及腹膜病灶无法 discrete 测量时难以计数,构成应用该分类系统的两大疾病特异性挑战。

临床怎么用

  • 在更有效全身治疗背景下,可考虑立体定向放疗用于精选的低转移负荷卵巢癌患者以实现持久局部控制。
  • 建议在 multidisciplinary 框架下由ESTRO-EORTC与欧洲妇科肿瘤学会合作制定卵巢癌特异性腹膜病变规则并统一试验入组。

局限性

  • 本文为观点性文章,未提供原始研究数据或验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The oligometastatic disease classification system, developed within the European Society for Radiotherapy and Oncology (ESTRO)-European Organisation for Research and Treatment of Cancer (EORTC) OligoCare project, has been proposed for prognostic stratification and clinical trial design across solid tumours. Its application to ovarian cancer, however, is challenged by two disease-specific features: early and often diffuse peritoneal spread and the difficulty of lesion enumeration when peritoneal deposits are not discretely measurable. Historically, radiotherapy has had a restricted role in ovarian cancer, largely because effective doses cannot be safely delivered to diffuse peritoneal disease in a condition that is typically systemic at diagnosis. With the advent of more effective systemic therapies, stereotactic radiotherapy has emerged as a strategy to reach durable local control in selected patients with minimal metastatic burden. Adapting the ESTRO-EORTC oligometastatic disease classification system to this setting could improve patient stratification and therapeutic planning. We therefore advocate for a joint ESTRO-EORTC-European Society of Gynaecological Oncology initiative, in collaboration with the EORTC Gynecological Cancer Group, to define ovarian-specific rules for peritoneal disease, refine patient selection, and harmonise clinical practice and trial eligibility within a multidisciplinary framework.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Macchia G, Morganti AG, Taylor A, et al. Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer. Lancet Oncol. 2026. PMID: 42636843. doi:10.1016/S1470-2045(26)00296-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。